Merck: Keytruda gets priority review for kidney cancer
(CercleFinance.com) - Merck said that US health regulators have assigned priority review status for its immuno-therapy drug Keytruda for the first-line treatment of patients with advanced renal cell carcinoma.
The FDA's decision is based on findings from a Phase III trial, which demonstrated that Keytruda, in combination with Pfizer's axitinib, significantly improved overall survival and progression-free-survival in the first-line treatment of the disease.
Many patients with advanced renal cell carcinoma face a poor prognosis, with few effective treatment options, Merck said.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
The FDA's decision is based on findings from a Phase III trial, which demonstrated that Keytruda, in combination with Pfizer's axitinib, significantly improved overall survival and progression-free-survival in the first-line treatment of the disease.
Many patients with advanced renal cell carcinoma face a poor prognosis, with few effective treatment options, Merck said.
Copyright (c) 2019 CercleFinance.com. All rights reserved.